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8 patients (19.0%). The only grade 3–5 treatment-related 
AE reported in at least two patients was anemia. There 
were two treatment-related deaths (unknown cause and cer-
ebral hemorrhage). Among the 37 evaluable patients, the 
confirmed overall response rates (ORRs) determined by 
central review were 24.1% (95% CI 10.3–43.5) for cutane-
ous melanoma and 25.0% (95% CI 3.2–65.1) for mucosal 
melanoma. The responses were durable, and the median 
duration of response was not reached in either population. 
The median overall survival (OS) was not reached, with a 
12-month OS of 82.7% for cutaneous melanoma and 51.4% 
for mucosal melanoma.
Conclusion The safety profile of pembrolizumab in 
Japanese patients was similar to that reported in the pre-
vious clinical studies. Pembrolizumab provided promis-
ing anti-tumor activity in Japanese patients with advanced 
melanoma.
Abstract 
Purpose This phase I b study evaluated the safety and 
anti-tumor activity of pembrolizumab in Japanese patients 
with advanced melanoma.
Methods Pembrolizumab (2  mg/kg) was given every 
3 weeks (Q3W) for up to 2 years or until confirmed pro-
gression or unacceptable toxicity. The tumor response was 
assessed as per the Response Evaluation Criteria in Solid 
Tumors version 1.1 (RECIST v1.1) by both investigator 
review and central review.
Results Forty-two patients with advanced melanoma 
received pembrolizumab. A primary cutaneous histol-
ogy was observed in 34 patients (81.0%), while a primary 
mucosal histology was observed in 8 patients (19.0%). 
Thirty-four patients (81.0%) experienced treatment-related 
adverse events (AEs). The most common treatment-related 
AEs were pruritus, maculopapular rash, malaise, and hypo-
thyroidism. Grade 3–5 treatment-related AEs occurred in 
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Introduction
The malignant cell in melanoma is the melanocyte. Because 
melanocytes are located in the basal layer of the epidermis, 
melanoma is most commonly seen on the skin. However, 
melanoma can also arise on mucosal surfaces, such as the 
oral cavity, the upper gastrointestinal mucosa, the genital 
mucosa, as well as the uveal tract of the eye and leptome-
ninges [1, 2]. Internationally, approximately 230,000 new 
cases of melanoma are diagnosed per year, with over 70% 
of these diagnosed in Australia, Europe, or North America 
[3, 4]. Melanoma is a rare disease in Asia. In Japan, approx-
imately 1300 new cases of melanoma were diagnosed and 
more than 600 patents died of melanoma in 2012, and the 
incidence is increasing [3]. The most common subtype of 
cutaneous melanoma in Caucasians is superficial spreading 
melanoma (SSM), accounting for approximately 60–70% 
of all melanomas [1]. In contrast, the most common sub-
type of cutaneous melanoma in Asia is acral lentiginous 
melanoma (ALM), accounting for approximately 50% of all 
melanomas [5–7]. ALM is the rare subtype in Caucasians, 
comprising <5% of cutaneous melanoma [6, 7]. The prog-
nosis of SSM is the most favorable among the cutaneous 
melanoma subtypes [5, 8]. Mucosal melanomas represent 
only about 1.3% of all melanomas. Unlike cutaneous mela-
nomas, mucosal melanomas are found at similar frequen-
cies among patients of Black, Hispanic, or Asian origin, 
compared with non-Hispanic Caucasians [2]. The progno-
sis of mucosal melanoma is poorer than those of ALM and 
non-ALM cutaneous melanoma [8, 9]. ALM and mucosal 
melanoma have distinct genetic characteristics, such as 
less common BRAF and RAS mutations and a higher fre-
quency of KIT mutations (10–20% for ALM, 15–20% for 
mucosal), compared to cutaneous melanomas (2%) [10–13] 
and a lower somatic mutational burden than that for SSM 
[14].
Pembrolizumab (formerly known as MK-3475) is a 
potent, highly selective, IgG4-k humanized monoclonal 
antibody that prevents programmed death 1 (PD-1) from 
binding with two ligands, programmed death ligand 1 (PD-
L1) and programmed death ligand 2 (PD-L2). This agent 
was generated by grafting the variable region sequences of 
a mouse antihuman PD-1 antibody onto a human IgG4-k 
isotype framework containing a stabilizing S228P mutation 
of the Fc region. The administration of pembrolizumab at 
a dose of 10 mg/kg every 3 weeks (Q3W), 10 mg/kg every 
2 weeks (Q2W), or 2  mg/kg Q3W resulted in ORRs of 
25–52% in an advanced melanoma expansion cohort of a 
phase 1 study (KEYNOTE-001) [15]. Pharmacokinetic and 
pharmacodynamic analyses showed that the lowest dose 
with the full potential for anti-tumor activity was 2  mg/
kg Q3W [16]. In a randomized phase 2 study performed 
in patients with ipilimumab-refractory melanoma (KEY-
NOTE-002), compared with chemotherapy, pembrolizumab 
at a dose of 2 or 10 mg/kg Q3W was well tolerated and sig-
nificantly improved progression-free survival (PFS), reduc-
ing the risk of death or disease progression by 43 and 50%, 
respectively [17]. In a randomized phase 3 study performed 
in patients with ipilimumab-naïve melanoma (KEY-
NOTE-006), pembrolizumab at a dose of 10 mg/kg Q3W 
or Q2W significantly improved the PFS and overall sur-
vival (OS), compared with ipilimumab, reducing the risk of 
death or disease progression by 42% and the risk of death 
by 31–37%, respectively, as well as being associated with 
fewer occurrences of high-grade toxicity [18]. Randomized 
clinical studies of pembrolizumab demonstrated that no 
clinically meaningful differences in the safety or efficacy of 
pembrolizumab were evident between 2  mg/kg Q3W and 
10 mg/kg Q3W or between 10 mg/kg Q3W and 10 mg/kg 
Q2W [17–20]. Thus, the administration of pembrolizumab 
at a dose of 2 mg/kg Q3W is currently approved in the US 
and over 60 other countries for the treatment of patients 
with advanced melanoma (unresectable or metastatic).
The safety and pharmacokinetic profiles for the Japa-
nese patients were similar to those previously reported for 
Caucasian patients in a phase 1 study examining the use of 
pembrolizumab in Japanese patients with advanced solid 
tumors (KEYNOTE-011) [21]. Therefore, in this study, the 
safety and anti-tumor activity of pembrolizumab at a dose 
of 2  mg/kg Q3W were investigated in Japanese patients 
with advanced melanoma.
Materials and methods
Patient eligibility
This study was conducted based on the Declaration of Hel-
sinki and the Guidelines for the Clinical Evaluation Meth-
ods of Anti-Cancer Drugs in Japan (Japanese Ministry 
of Health, Labor, and Welfare notification, November 1, 
2005). The study was approved by the institutional review 
board of each study site.
The main eligibility criteria were as follows: a histologi-
cally confirmed diagnosis of locally advanced (unresect-
able Stage III) or metastatic (Stage IV) melanoma not ame-
nable to local therapy; 0–2 prior lines of therapy (excluding 
adjuvant or neoadjuvant therapy) for melanoma; a patient 
age of 20 years or older; at least one measurable lesion as 
defined by RECIST v1.1; an Eastern Cooperative Oncology 
Group (ECOG) performance status of 0 or 1; and adequate 
hematologic, hepatic, and renal functions. The exclusion 
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criteria included the administration of chemotherapy, radio-
therapy, or biological therapy during the 4 weeks prior to 
enrollment; the previous treatment with a PD-1, PD-L1, 
or cytotoxic T-lymphocyte-associated protein 4 inhibitor; 
untreated and/or unstable central nervous system metasta-
sis; or the presence of autoimmune disease.
All the patients provided informed consent, and the 
study was conducted in accordance with current Good 
Clinical Practice standards. This study was registered at 
ClinicalTrials.gov as NCT02180061.
Study design and evaluation
This study was an open-label, non-randomized, multi-
center phase Ib study of pembrolizumab in Japanese 
patients with advanced melanoma conducted at 12 sites 
in Japan. Pembrolizumab at a dose of 2 mg/kg Q3W was 
administered intravenously during a 30-min period, and 
treatment was continued until disease progression, the 
onset of unacceptable side effects, an investigator’s deci-
sion to discontinue treatment, the withdrawal of patient 
consent, or 24 months of therapy. Patients with a con-
firmed complete response who had received pembroli-
zumab for at least 6 months were allowed to discontinue 
therapy after receiving at least two doses beyond the deter-
mination of a complete response. The primary objectives 
of this study were to determine the safety, tolerability, and 
overall response rate (ORR) per RECIST v1.1 in patients 
with advanced cutaneous melanoma. The secondary objec-
tives included evaluations of the duration of response and 
PFS per RECIST v1.1 as well as the OS in patients with 
advanced cutaneous melanoma. As exploratory objectives, 
the efficacy (ORR, duration of response, and PFS) of the 
treatment per RECIST v1.1 and the OS were also evaluated 
in patients with advanced mucosal melanoma.
Patients were evaluated using radiographic imaging 
to assess the response to treatment every 6 weeks start-
ing at 12 weeks and continuing until 48 weeks; after 48 
weeks, the patients were evaluated every 12 weeks. Tumor 
response was assessed using RECIST v1.1 by both investi-
gator review and central review. If clinically stable, patients 
with first radiologic evidence of disease progression per 
RECIST v1.1 were permitted to continue receiving pem-
brolizumab until a second scan performed ≥4 weeks there-
after confirmed progression. Adverse events (AEs) were 
monitored throughout the study and were graded for sever-
ity according to the guidelines outlined in the NCI Com-
mon Terminology Criteria for Adverse Events (CTCAE), 
version 4.0.
Participation in this study required that an archival tis-
sue sample or a newly obtained biopsy of a tumor lesion 
not previously irradiated be submitted for an evaluation 
of PD-L1 expression, which was conducted at a central 
laboratory. The expression status of PD-L1 was evalu-
ated using immunohistochemistry (IHC) and the 22C3 
antibody. PD-L1 positivity was defined as membranous 
PD-L1 expression in ≥1% of the tumor cells and associated 
immune cells. Both PD-L1 positive and negative patients 
were enrolled in this trial, and the clinical activities were 
evaluated in both subsets as pre-defined subgroups.
Statistical analysis
Patients with advanced cutaneous melanoma were included 
in the primary efficacy analysis population. A confirmed 
ORR per RECIST v1.1, as assessed by central review, in 
patients with advanced cutaneous melanoma was used as 
the primary endpoint for the efficacy assessment. The full 
analysis set (FAS) population was used to analyze the effi-
cacy data in this study. The FAS population consisted of 
all allocated patients with measurable lesions at the base-
line scan, as assessed by central review, who had received 
at least one dose of the study treatment. The 95% confi-
dence interval and a one-sided P value for testing the null 
hypothesis (ORR = 10%) based on a binomial distribution 
were calculated for the response rate. With approximately 
28 evaluable patients with advanced cutaneous melanoma, 
the study had an approximately 90% power to detect a 25% 
difference in ORR under the null hypothesis of ORR = 10% 
with a type I error rate of 2.5% if the true ORR was 35%. 
The PFS, OS, and duration of response were estimated 
using the Kaplan–Meier method. The ASaT population 
was used for the primary safety analysis in this study. The 
ASaT population consisted of all the allocated patients who 
had received at least one dose of pembrolizumab. Immune-
related AEs that were previously identified as important 
risks associated with pembrolizumab use were collected as 
Adverse Events of Special Interest (AEOSI). The AEOSIs 
included pneumonitis, colitis, thyroid disorders, hepati-
tis, hypophysitis, type 1 diabetes mellitus, uveitis, myosi-
tis, severe skin reactions, pancreatitis, nephritis, Guil-
lain–Barré syndrome, and infusion-related reactions.
Results
Patient characteristics
Between July 2014 and March 2015, a total of 42 Japa-
nese patients with advanced melanoma were enrolled in 
this study at 12 study sites in Japan and were treated with 
pembrolizumab (2 mg/kg Q3W). At the time of data cutoff 
(August 20, 2015), the median duration of follow-up was 
10.3 months (range 2.6–12.6 months). The baseline char-
acteristics of the patients are summarized in Table 1. The 
patients had a median age of 65 years (range 39–89 years), 
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61.9% were male, 81.0% had an ECOG performance status 
of 0, and 59.6% had not received any prior systemic ther-
apy for advanced melanoma. A primary cutaneous histol-
ogy was observed in 34 patients (81.0%), while a primary 
mucosal histology was observed in 8 patients (19.0%). The 
most frequent subtypes of melanoma were acral lentiginous 
melanoma (ALM: 12/42, 28.6%) and nodular melanoma 
(10/42, 23.8%). The BRAF V600 mutation was observed in 
16.7% of the patients, and 50% had PD-L1-positive tissue 
samples. The median duration of treatment was 212.5 days 
(range 1.0–385.0 days), and the median number of treat-
ments was 11.0 (range, 1.0–19.0). At the time of the analy-
sis, 21 patients had discontinued pembrolizumab treatment: 
5 because of an AE, 3 because of clinical progression, and 
13 because of disease progression.
Safety
Forty-two patients were treated with pembrolizumab 
(2 mg/kg Q3W), and all the patients were included in the 
safety analysis. The treatment-related AEs reported for all 
treatment cycles are summarized in Table  2. Thirty-four 
patients (81.0%) had at least one treatment-related AE of 
any grade. The most common treatment-related AEs were 
pruritus (n = 6, 14.3%), maculopapular rash (n = 6, 14.3%), 
malaise (n = 5, 11.9%), hypothyroidism (n = 4, 9.5%), viti-
ligo (n = 3, 7.1%), diarrhea (n = 3, 7.1%), an elevated AST 
level (n = 3, 7.1%), and an elevated eosinophil count (n = 3, 
7.1%). Grade 3–5 treatment-related AEs occurred in 8 
patients (19.0%). The only grade 3–5 treatment-related AE 
that was reported in at least 2 patients was anemia (4.8%). 
Two deaths (4.8%, unknown cause and cerebral hemor-
rhage) occurred and were considered by the investigator to 
have been related to the pembrolizumab treatment. Other 
than the above-mentioned 2 fatalities, 3 patients discontin-
ued the pembrolizumab treatment because of a treatment-
related AE (grade 2 arthralgia and grade 2 myalgia in one 
patient, grade 2 pneumonitis and grade 2 lung infection 
in one patient, and grade 2 hypophysitis in one patient). 
AEs of special interest based on a likely autoimmune or 
immune-related mechanism (irrespective of whether they 
were attributed to pembrolizumab by the investigator) 
occurred in 13 (31.0%) of the 42 patients. These events 
were hypothyroidism (n = 5, 11.9%), hypophysitis (n = 3, 
7.1%), hyperthyroidism (n = 2, 4.8%), colitis (n = 2, 4.8%), 
infusion reaction (n = 2, 4.8%), pneumonitis (n = 1, 2.4%), 
severe skin reaction (n = 1, 2.4%), and uveitis (n = 1, 2.4%). 
The AEs of special interest with a severity of grade 3–5 
were grade 3 colitis and grade 3 hypophysitis (n = 1 each).
Efficacy
Among the 42 enrolled patients, 37 were evaluable for 
the tumor response performed by central review. Five 
patients without measurable lesions at baseline accord-
ing to central review were excluded from the analysis. 
Of the 37 patients, 29 had cutaneous melanoma (primary 
efficacy evaluation population) and 8 had mucosal mela-
noma. The tumor response results per RECIST v1.1 are 
summarized in Table 3 and Fig. 1. A waterfall plot shows 
that 75.7% (28/37) of the patients experienced some degree 
of tumor shrinkage. The confirmed ORR, as assessed by 
Table 1  Baseline patient characteristics
ECOG Eastern Cooperative Oncology Group, NM nodular mela-
noma, SSM superficial spreading melanoma, LMM lentigo maligna 
melanoma, ALM acral lentiginous melanoma, NC not classified, LDH 
lactate dehydrogenase
a Defined as membranous PD-L1 expression in >1% of tumor cells 
and associated immune cells as assessed using IHC with the 22C3 
antibody
Characteristics All treated 
patients 
(n = 42)
Age, year, median (range) 65 (39–89)
Sex, n (%)
 Male 26 (61.9)
 Female 16 (38.1)
ECOG performance status, n (%)
 0 34 (81.0)
 1 8 (19.0)
Tumor types, n (%)
 Cutaneous melanoma 34 (81.0)
 NM 10 (23.8)
 SSM 7 (16.7)
 LMM 1 (2.4)
 ALM 12 (28.6)
 NC 4 (9.5)
 Mucosal melanoma 8 (19.0)
BRAF status, n (%)
 Mutant 7 (16.7)
 Wild 33 (78.6)
 Undetermined 2 (4.8)
LDH, n (%)
 Normal 41 (97.6)
 Elevated 1 (2.4)
PD-L1  expressiona, n (%)
 Positive 21 (50.0)
 Negative 13 (31.0)
 Undetermined 8 (19.0)
Prior systemic therapies, n (%)
 None 12 (28.6)
 Adjuvant/neoadjuvant 13 (31.0)
 1 13 (31.0)
 2 4 (9.5)
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central review, was 24.1% for the patients with cutane-
ous melanoma (7/29; 95% CI 10.3–43.5), and the lower 
limit of the 95% CI exceeded the 10% threshold response 
rate (P = 0.0216). The median time to response was 12.3 
weeks among the patients with cutaneous melanoma. The 
responses were durable, and the median DOR was not 
reached; 5 (71.4%) of the 7 responders with cutaneous mel-
anoma remained progression-free. The confirmed ORR, as 
assessed by central review, was 25.0% for the patients with 
mucosal melanoma (2/8; 95% CI 3.2–65.1). The median 
time to response was 17.8 weeks among the patients with 
mucosal melanoma. The median DOR was not reached, 
and 2 (100%) of the 2 responders with mucosal mela-
noma remained progression-free. Similar tumor response 
results were obtained by investigator review (Table  3). 
Kaplan–Meier curves of PFS per RECIST v1.1 by 
central review and OS are shown in Fig.  2. The median 
PFS as assessed by central review was 4.2 months (95% 
CI 2.8–7.0) for the patients with cutaneous melanoma, 
with a 6-month PFS rate of 41.4%. The median PFS was 
3.4 months (95% CI 2.1–NA) for the patients with mucosal 
melanoma, with a 6-month PFS rate of 37.5%. The median 
OS was not reached in either population, with a 12-month 
OS rate of 82.7% for the patients with cutaneous melanoma 
and 51.4% for the patients with mucosal melanoma.
Tumor tissues from 42 patients were available for use in 
a PD-L1 expression immunohistochemistry assay. PD-L1 
positivity was defined as membranous PD-L1 expression 
in ≥1% of the tumor cells and associated immune cells 
as assessed using IHC with the 22C3 antibody. PD-L1 
expression was positive in tumor samples from 21 patients 
(50.0%) and negative in tumor samples from 13 patients 
(31.0%). The PD-L1 status was not determined in tumor 
samples from eight patients (19.0%): seven patients had 
excessive melanin pigment in their tumor tissues, and one 
did not have a tumor with a defined border. The confirmed 
ORR as assessed by central review for both cutaneous and 
mucosal melanoma was 16.7% (3/18; 95% CI 3.6–41.4) for 
the patients with PD-L1-positive tumors and 36.4% (4/11; 
95% CI 10.9–69.2) for the patients with PD-L1-negative 
tumors. The median PFS was 2.8 months, with a 6-month 
PFS rate of 27.8%, for the PD-L1 positive subgroup, while 
the median PFS was 5.4 months, with a 6-month PFS rate 
of 45.5%, for the PD-L1-negative subgroup. The OS was 
favorable for the PD-L1-positive subgroup (1-year OS rate: 
83.3%), compared with that for the PD-L1-negative sub-
group (1-year OS rate: 72.5%).
Discussion
The primary objective of this study was to investigate 
the safety of single-agent pembrolizumab and the tumor 
response in Japanese patients with advanced melanoma. 
The dosing schedules in this study were 2  mg/kg Q3W, 
which is the approved dose for the treatment of advanced 
melanoma in the US and other countries. The safety profile 
of the Japanese patients with advanced melanoma was sim-
ilar to that observed in clinical studies of pembrolizumab 
in non-Japanese patients [15–20]. The most common 
treatment-related AEs, which were reported in 3 patients 
or more, were pruritus, maculopapular rash, malaise, hypo-
thyroidism, vitiligo, diarrhea, an elevated AST level, and 
an elevated eosinophil count. Grade 3–5 treatment-related 
AEs occurred in 19.0% of the patients. The only grade 3–5 
treatment-related AE that was reported in at least 2 patients 
was anemia. Immune-related AEs occurred in 31.0% of the 
patients and included hypothyroidism, hypophysitis, coli-
tis, hyperthyroidism, infusion reaction, pneumonitis, severe 
Table 2  Treatment-related adverse events occurring in two or more 
patients with advanced melanoma after treatment with pembroli-
zumab
AST aspartate aminotransferase, ALT alanine aminotransferase
a Other grade 3–5 treatment-related AEs were grade 5 cerebral hem-
orrhage, grade 5 death from unknown cause, grade 4 hyperglycemia, 
grade 3 lymphopenia, grade 3 bile duct obstruction, grade 3 encepha-
lopathy, and grade 3 drug eruption (n = 1 each)
Adverse events All treated patients 
(n = 42)
Any grade Grade 3–5a
Skin and subcutaneous tissue disorders
 Pruritus 6 (14.3) 0
 Maculopapular rash 6 (14.3) 0
 Vitiligo 3 (7.1) 0
 Skin hypopigmentation 2 (4.8) 0
 Dry skin 2 (4.8) 0
General disorders and administration site conditions
 Malaise 5 (11.9) 0
Endocrine disorders
 Hypothyroidism 4 (9.5) 0
 Hyperthyroidism 2 (4.8) 0
 Hypophysitis 2 (4.8) 1 (2.4)
Gastrointestinal disorders
 Diarrhea 3 (7.1) 0
 Nausea 2 (4.8) 0
 Abdominal pain 2 (4.8) 0
 Upper abdominal pain 2 (4.8) 0
 Colitis 2 (4.8) 1 (2.4)
Laboratory results
 Elevated AST 3 (7.1) 0
 Elevated eosinophil count 3 (7.1) 0
 Elevated ALT 2 (4.8) 0
Blood and lymphatic system disorders
 Anemia 2 (4.8) 2 (4.8)
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skin reaction, and uveitis. Immune-related AEs are distinct 
in both their mechanisms and management from AEs com-
monly associated with chemotherapy. The early recognition 
and treatment are essential to prevent morbidity and mor-
tality, and adherence to established algorithms is recom-
mended [22]. In this study, most immune-related AEs were 
of grade 1 or 2 and were manageable by interrupting the 
pembrolizumab treatment and/or providing medical inter-
vention with steroid therapy and appropriate supportive 
care. At the time of the database cut-off date, one case of 
hypophysitis was not resolved; however, all the other events 
were alleviated or resolved, with the exception of events 
resulting in death.
In this study, the tumor response in patients with cutane-
ous melanoma was evaluated as the primary objective, and 
the tumor response in patients with mucosal melanoma was 
evaluated as an exploratory objective. The confirmed ORR 
as assessed by central review was 24.1% (7/29; 95% CI 
10.3–43.5) for the patients with cutaneous melanoma, with 
the lower limit of the 95% CI exceeding the 10% thresh-
old response rate (P = 0.0216), while the confirmed ORR 
was 25.0% (2/8; 95% CI 3.2–65.1) for the patients with 
mucosal melanoma. This study demonstrated the thera-
peutic benefits of pembrolizumab in Japanese patients with 
advanced cutaneous melanoma. The responses were dura-
ble, and the median DOR was not reached in either popu-
lation. The study population of KEYNOTE-041 was ipili-
mumab-naïve, and 59.6% of the patients had not received 
any prior systemic therapy for advanced melanoma. Com-
pared with the results from KEYNOTE-006, a randomized 
phase 3 trial comparing ipilimumab to pembrolizumab in 
non-Japanese patients with ipilimumab-naïve melanoma, 
the ORR for cutaneous melanoma was numerically lower 
than that (32.9–33.7%) observed in KEYNOTE-006, but 
the waterfall plots for both of the studies were similar. Pem-
brolizumab showed anti-tumor activity regardless of the 
PD-L1 expression status, though the sample sizes used for 
the subgroup analyses in this study were limited. Additional 
long-term OS analyses for KEYNOTE-041 were made 
with a data cut-off date of September 23, 2016 (median 
follow-up duration, 22. 0 months; range, 2.6–25.8 months). 
The median OS for the patients with cutaneous melanoma 
was 25.1 months (95% CI 15.8–25.1), with 12-month and 
24-month OS rates of 76.1 and 57.0%, respectively. The 
median OS for the patients with mucosal melanoma was 
23.2 months (95% CI 15.8–25.1), with 12-month and 
24-month OS rates of 51.4 and of 25.7%, respectively. The 
OS results for cutaneous melanoma were similar to the final 
OS results for KEYNOTE-006 (12-month and 24-month 
OS rates of 68–74 and 55%, respectively) [23]. These OS 
results were consistent with those of the previous reports, 
which concluded that the prognosis of mucosal melanoma 
was poorer than that of cutaneous melanoma [8, 9].
The most frequent melanoma in this study was acral 
lentiginous melanoma (ALM, n = 12), followed by nodular 
melanoma (n = 10) and mucosal melanoma (n = 8). In this 
study, among the 12 patients with ALM, 2 had a CR and 1 
had a PR, for an ORR of 25.0%. Recently, Shoushtari et al. 
reported that the ORR was 32.0% for patients with acral 
melanoma (n = 25) receiving pembrolizumab or nivolumab 
and 22.9% for those with mucosal melanoma (n = 35) [24]. 
On the other hand, the ORR for patients with metastatic 
Table 3  Tumor response in patients with advanced melanoma treated with pembrolizumab
NR not reached
Cutaneous melanoma
n (%; 95% CI)
Mucosal melanoma
n (%; 95% CI)
Total
n (%; 95% CI)
Central review (n = 29) (n = 8) (n = 37)
 Overall response 7 (24.1%, 10.3–43.5) 2 (25.0%, 3.2–65.1) 9 (24.3%, 11.8–41.2)
 Complete response 2 (6.9%, 0.8–22.8) 0 2 (5.4%, 0.7–18.2)
 Partial response 5 (17.2%, 5.8–35.8) 2 (25.0%, 3.2–65.1) 7 (18.9%, 8.0–35.2)
 Stable disease 7 (24.1%, 10.3–43.5) 2 (25.0%, 3.2–65.1) 9 (24.3%, 11.8–41.2)
 Progressive disease 14 (48.3%, 29.4–67.5) 4 (50.0%, 15.7–84.3) 18 (48.6%, 31.9–65.6)
 Non-evaluable 1 (3.4%, 0.1–17.8) 0 1(2.7%, 0.1–14.2)
Investigator review (n = 34) (n = 8) (n = 42)
 Overall response 9 (26.5%, 12.9–44.4) 3 (37.5%, 8.5–75.5) 12 (28.6%, 15.7–44.6)
 Complete response 2 (5.9%, 0.7–19.7) 0 2 (4.8%, 0.6–16.2)
 Partial response 7 (20.6%, 8.7–37.9) 3 (37.5%, 8.5–75.5) 10 (23.8%, 12.1–39.5)
 Stable disease 14 (41.2%, 24.6–59.3) 2 (25.0%, 3.2–65.1) 16 (38.1%, 23.6–54.4)
 Progressive disease 11 (32.4%, 17.4–50.5) 3 (37.5%, 8.5–75.5) 14 (33.3%, 19.6–49.5)
Median time to response, weeks (range) 12.3 (12–18) 17.8 (12–24) 12.3 (12–24)
Median duration of response, weeks (range) NR (17 to 37+) NR (24+ to 36+) NR (17 to 37+)
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Fig. 1  Anti-tumor activity of 
pembrolizumab per RECIST 
v1.1 by central review. a Best 
change from baseline in the 
sum of the longest target lesion 
diameters for each patient. b 
Treatment exposure and dura-
tion of response per patient. 
c Longitudinal changes in the 
sum of the longest target lesion 
diameters for each patient
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uveal melanoma (n = 56) receiving pembrolizumab, 
nivolumab, or atezolizumab was reported to be 3.6% [25]. 
Patients with metastatic uveal melanoma were not enrolled 
in this study, because they were excluded according to the 
eligibility criteria. The anti-tumor activity of anti-PD-1 
antibodies for advanced melanoma differed, depending on 
the subpopulation. Though the numbers of patients with 
ALM and mucosal melanoma were limited in this study, the 
ORR results were similar to those reported by Shoushtari 
et al. These results support the concept that pembrolizumab 
provides therapeutic benefits to certain subpopulations of 
patients, such as those with ALM or mucosal melanoma. 
Because of the rarity of mucosal melanoma, prospective 
clinical studies assessing the efficacy of systemic therapy 
have been rare, though a high, unmet medical need exists. 
Consequently, there are no standard guidelines for the 
treatment of mucosal melanoma at present. Therefore, to 
accelerate the development of treatment strategies for rare 
cancers, such as ALM and mucosal melanoma, a proactive 
approach to conducting clinical studies in countries/area 
with a relatively high incidence of the cancer is likely to 
become more and more important.
Recently, combination immunotherapy with ipilimumab 
and nivolumab received FDA and EMA approval. The com-
bination of ipilimumab and nivolumab showed higher ORR 
of 57.6% as first-line treatment compared with each indi-
vidual monotherapy. However, the combination induced 
55.0% grade 3–4 treatment-related AEs and treatment dis-
continuation rates of 36.4% [26]. Therefore, a novel combi-
nation treatment with promising efficacy and less toxicity 
is still desired. The early clinical studies of pembrolizumab 
in combination with low-dose ipilimumab (1 mg/kg), tali-
mogene laherparepvec (T-VEC), or epacadpstat, a selective 
oral inhibitor of indoleamine 2,3-dioxygenase 1(IDO1), 
showed acceptable safety profiles and promising efficacy in 
patients with advanced melanoma [27–29]. Phase 3 stud-
ies of pembrolizumab plus T-VEC, and pembrolizumab 
plus epacadostat are currently on-going in patients with 
advanced melanoma. Based on the positive results from 
this study, Japan is participating in the randomized phase 
3 study of pembrolizumab versus placebo as adjuvant ther-
apy after complete resection of high-risk stage III mela-
noma (EORTC1325/KEYNOTE-054), and will participate 
in phase 3 studies of combinations with pembrolizumab in 
advanced melanoma in the near future.
In conclusion, the safety profile of pembrolizumab in 
Japanese patients with advanced melanoma was similar to 
that reported in the previous studies. Pembrolizumab pro-
vided promising anti-tumor activity, supporting further 
clinical development of pembrolizumab for the treatment 
of Japanese patients with resectable stage III or advanced 
melanoma.
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